Clinical Trials Browser

Phase 2 × OTHER_GOV × dalpiciclib × Clear all

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Phase 2 Not yet recruiting

Breast Neoplasms